We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon Beta (IFN-β) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.
Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. In Episode 1, Not All Antivirals Are the Same, Professor Tom Wilkinson from the University of Southampton and Vicki Tear, Vice President, Non-Clinical Operations, Synairgen, discuss how antiviral agents work on viruses and the potential benefits of broad-spectrum host-directed antivirals. Episode 2 includes Professor Ratko Djukanovic, Professor of Medicine at University of Southampton and Richard Marsden, CEO of Synairgen, continuing the discussion with a focus on understanding the broad-spectrum antiviral protein, IFN-β.
Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.
There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.
people in US hospitalised annually from 2022 onwards due to severe VRIssource: IQVIA market research Q4 2022; Sources: US CDC, HCUP, IQVIA Claims Data, PubMed; data on file
in the US, representing a population at significant risk for severe RVIssource: American Medical Association
The estimated annual US healthcare costs related to severe VRIssources: Hartnet J. Influenza Other Respi Viruses. 2022;16:906–915; Pastula ST et.al.,OFID, 2017,ofw270; Zhou JA et.al., CID, 2020, 70(5): 773-779; Disease Burden of Flu | CDC; Preliminary Medicare COVID-19 Data Snapshot (Dec 2021); ICER Report: Special Assessment of Outpatient Treatments for COVID-19 Feb 2022
It Ain’t Over Till It’s Over…but It’s Never OverDr. Anthony Fauci, New England Journal of Medicine, 26 November 2022